KOREA WHO
-
-
Chairman of HLB
Jin Yang-gon
Advocating "People-Centered Management," Inspired by Chung Ju-yung, and Retrying U.S. Approval for Rivoceranib
-
Last Updated on Feb 13, 2025
-
Chairman of HLB
Copy Url : https://www.koreawho.com/profile/JinYanggon- Life Summary
Jin Yang-gon is the Chairman and CEO of HLB.
He is focused on the commercialization of new drugs, including the anticancer drug "Rivoceranib," and securing growth momentum through mergers and acquisitions.
He was born on January 14, 1966, in Busan.
He graduated from Wonkwang University with a degree in law and earned a master's degree in business administration from Yonsei University Graduate School.
After working at Busan Bank and Peace Bank, he left the banking sector and ran a pub.
In 1998, he founded the consulting firm J&Lee Partners.
In 2004, he established the investment company Golden Light and entered the mergers and acquisitions business. After acquiring HLB, he ventured into the biotechnology industry.
He has applied for U.S. Food and Drug Administration (FDA) approval for Rivoceranib as a liver cancer treatment and is preparing for commercialization.
He advocates for people-centered management.
#HLB #biotech #pharmaceuticals #Rivoceranib #FDAapproval #anticancerdrug #businessleadership #mergersandacquisitions #Korea #healthcare
He is focused on the commercialization of new drugs, including the anticancer drug "Rivoceranib," and securing growth momentum through mergers and acquisitions.
He was born on January 14, 1966, in Busan.
He graduated from Wonkwang University with a degree in law and earned a master's degree in business administration from Yonsei University Graduate School.
After working at Busan Bank and Peace Bank, he left the banking sector and ran a pub.
In 1998, he founded the consulting firm J&Lee Partners.
In 2004, he established the investment company Golden Light and entered the mergers and acquisitions business. After acquiring HLB, he ventured into the biotechnology industry.
He has applied for U.S. Food and Drug Administration (FDA) approval for Rivoceranib as a liver cancer treatment and is preparing for commercialization.
He advocates for people-centered management.
#HLB #biotech #pharmaceuticals #Rivoceranib #FDAapproval #anticancerdrug #businessleadership #mergersandacquisitions #Korea #healthcare
- Life Summary
- Career Highlights & Challenges
- · Expanding Stake in HLB Affiliates, Strengthening Commitment to Responsible Management
- · Accelerating Next-Generation Drug Development
- · Retrying U.S. FDA Approval for Rivoceranib
- · Expanding the "HLB Ecosystem" Through Aggressive M&A
- · HLB Plans KOSPI Transfer Listing
- · HLB Reports Poor 2023 Performance Due to Decline in COVID-19 Diagnostics
- · Establishing a Specialized Firm for New Business Development
- · Strengthening HLB Group’s Identity
- · Acquiring Global Rights for Anticancer Drug Rivoceranib
- · Eleva Therapeutics Becomes a Wholly Owned Subsidiary of HLB
- · Acquisition and Sale of HiCell
- · Entering the Biopharmaceutical Industry Through Lifeboat Manufacturer InnoGND (Now HLB)
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Family & Personal Connections
- Additional Information
- Notable Quotations
- Infographic & Photos